Drugs / Piperacillin/tazobactam
last change Dec 2023 re-read 2 minutes ago

Piperacillin/tazobactam

Developed for
bacterial infectious disease
Investigated by
Associazione Oncologica Milanese AmoLaVita ONLUS · Ospedale San Carlo Borromeo

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04816968 Sep 2021 → Sep 2023 bacterial infectious disease Ospedale San Carlo Borromeo Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Piperacillin/tazobactam ClinicalTrials.gov intervention name — accepted as the source's own label NCT04816968
Route Other “Continuous infusion of Piperacillin/tazobactam at home.” NCT04816968